Some good news on the vaccine front. European regulators are set to start an accelerated review of the candidate from AstraZeneca and the University of Oxford, according to a person familiar. And BioNTech and Pfizer said its vaccine Phase 1 trial in Germany showed a strong immune response to the virus. Yet, Moderna won't be able to apply for FDA emergency use authorization for its vaccine before Nov. 25, the FT reported, citing the company's CEO.